Volume 12, Issue 2, Pages (February 2011)

Slides:

Advertisements

Similar presentations

Volume 14, Issue 4, Pages (April 2013)

Advertisements

Volume 12, Issue 9, Pages (September 2011)

Volume 16, Issue 2, Pages (February 2015)

Volume 12, Issue 11, Pages (October 2011)

Volume 376, Issue 9747, Pages (October 2010)

Volume 18, Issue 7, Pages (July 2017)

Volume 17, Issue 8, Pages (August 2016)

Volume 16, Issue 9, Pages (September 2015)

Volume 388, Issue 10058, Pages (November 2016)

Volume 15, Issue 6, Pages (May 2014)

Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis Ian Cromwell, MSc, Kimberly.

A Systematic Review and Meta-analysis of the Literature: Chemotherapy and Surgery versus Surgery Alone in Non-small Cell Lung Cancer Sarah Burdett, MSc,

Volume 5, Issue 4, Pages (April 2006)

Volume 14, Issue 4, Pages (April 2013)

Volume 377, Issue 9779, Pages (May 2011)

Volume 377, Issue 9783, Pages (June 2011)

Intraoperative radiotherapy for early breast cancer

Low-level laser therapy for neck pain

Volume 13, Issue 3, Pages (March 2012)

Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled.

Volume 17, Issue 8, Pages (August 2016)

Volume 5, Issue 3, Pages (March 2018)

Volume 15, Issue 4, Pages (April 2014)

Volume 376, Issue 9757, Pages (December 2010)

Volume 374, Issue 9707, Pages (December 2009)

Volume 10, Issue 6, Pages (June 2009)

Volume 15, Issue 4, Pages (April 2014)

Volume 373, Issue 9663, Pages (February 2009)

Volume 15, Issue 4, Pages (April 2014)

Volume 9, Issue 10, Pages (October 2008)

Volume 14, Issue 8, Pages (July 2013)

Volume 18, Issue 7, Pages (July 2017)

Volume 14, Issue 8, Pages (July 2013)

Volume 12, Issue 7, Pages (July 2011)

Volume 15, Issue 6, Pages (May 2014)

Volume 385, Issue 9969, Pages (February 2015)

Volume 18, Issue 3, Pages (March 2017)

Volume 15, Issue 1, Pages (January 2014)

Volume 6, Issue 6, Pages (June 2005)

Volume 13, Issue 1, Pages (January 2012)

Volume 14, Issue 11, Pages (October 2013)

Volume 385, Issue 9962, Pages (January 2015)

Volume 15, Issue 8, Pages (July 2014)

Volume 371, Issue 9625, Pages (May 2008)

Volume 388, Issue 10058, Pages (November 2016)

Volume 5, Issue 3, Pages (March 2018)

Volume 371, Issue 9627, Pages (May 2008)

Volume 376, Issue 9757, Pages (December 2010)

Volume 16, Issue 15, Pages (November 2015)

Volume 9, Issue 4, Pages (April 2008)

Volume 14, Issue 6, Pages (May 2013)

Volume 16, Issue 15, Pages (November 2015)

Volume 373, Issue 9658, Pages (January 2009)

Volume 17, Issue 8, Pages (August 2016)

Volume 14, Issue 8, Pages (July 2013)

Volume 373, Issue 9658, Pages (January 2009)

Volume 375, Issue 9714, Pages (February 2010)

Volume 15, Issue 6, Pages (May 2014)

Volume 13, Issue 1, Pages (January 2012)

Volume 11, Issue 3, Pages (March 2010)

Volume 11, Issue 1, Pages (January 2010)

Volume 376, Issue 9757, Pages (December 2010)

Volume 371, Issue 9618, Pages (March 2008)

Volume 375, Issue 9715, Pages (February 2010)

Volume 376, Issue 9747, Pages (October 2010)

Volume 13, Issue 7, Pages (July 2014)

Volume 13, Issue 5, Pages (May 2012)

A Systematic Review and Meta-analysis of the Literature: Chemotherapy and Surgery versus Surgery Alone in Non-small Cell Lung Cancer Sarah Burdett, MSc,

Recurrence after low-dose radioiodine ablation and recombinant human thyroid- stimulating hormone for differentiated thyroid cancer (HiLo): long-term results.

Volume 14, Issue 7, Pages (June 2013)

Presentation transcript:

Volume 12, Issue 2, Pages 127-136 (February 2011) Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial Dr Christopher M Nutting, FRCR, James P Morden, MSc, Kevin J Harrington, FRCR, Teresa Guerrero Urbano, PhD, Shreerang A Bhide, FRCR, Catharine Clark, PhD, Elizabeth A Miles, MPhil, Aisha B Miah, FRCR, Kate Newbold, FRCR, MaryAnne Tanay, MSc, Fawzi Adab, FRCR, Sarah J Jefferies, FRCR, Christopher Scrase, FRCR, Beng K Yap, FRCR, Roger P A'Hern, MSc, Mark A Sydenham, BSc, Marie Emson, BSc, Emma Hall, PhD The Lancet Oncology Volume 12, Issue 2, Pages 127-136 (February 2011) DOI: 10.1016/S1470-2045(10)70290-4 Copyright © 2011 Elsevier Ltd Terms and Conditions

Figure 1 Study profile IMRT=intensity-modulated radiotherapy. The Lancet Oncology 2011 12, 127-136DOI: (10.1016/S1470-2045(10)70290-4) Copyright © 2011 Elsevier Ltd Terms and Conditions

Figure 2 Proportion of patients reporting grade 2 or worse LENT SOMA subjective xerostomia and RTOG salivary gland side-effects p values quoted compare proportions with grade 2 or worse side-effects in each group with a χ2 test. Error bars represent 95% CIs. IMRT=intensity-modulated radiotherapy. LENT SOMA=Late Effects of Normal Tissues Subjective-Objective Management Analytic. RTOG=Radiation Therapy Oncology Group. The Lancet Oncology 2011 12, 127-136DOI: (10.1016/S1470-2045(10)70290-4) Copyright © 2011 Elsevier Ltd Terms and Conditions

Figure 3 Mean EORTC HN35 dry mouth subscale score changes from baseline IMRT=intensity-modulated radiotherapy. EORTC HN35=European Organization for Research and Treatment of Cancer head and neck specific module HN35. The Lancet Oncology 2011 12, 127-136DOI: (10.1016/S1470-2045(10)70290-4) Copyright © 2011 Elsevier Ltd Terms and Conditions

Figure 4 Kaplan-Meier plot of locoregional progression-free survival by treatment group Hazard ratio 1·53 (95% CI 0·63 to 3·70). Log-rank test p=0·34. 2-year locoregional progression-free survival estimates for conventional radiotherapy 80% (95% CI 65 to 90) and for IMRT 78% (62 to 87); absolute difference 3% (–15 to 20). IMRT=intensity-modulated radiotherapy. The Lancet Oncology 2011 12, 127-136DOI: (10.1016/S1470-2045(10)70290-4) Copyright © 2011 Elsevier Ltd Terms and Conditions